Information Provided By: 
Fly News Breaks for February 16, 2018
PCRX, HRTX
Feb 16, 2018 | 05:18 EDT
Jefferies analyst Biren Amin believes the FDA panel for Pacira Pharmaceuticals' (PCRX) Exparel as a nerve block for regional analgesia suggests Heron Therapeutics' (HRTX) HTX-011 is in the "driver's seat." HTX-011's ongoing pivotal studies should address all these issues raised by FDA, Amin tells investors in a research note. He notes the FDA stated that the current studies failed to support Exparel's benefit as a long-lasting pain control, and failed to show an opioid-sparing-effect. The analyst keeps a Buy rating on Heron with a $26 price target.
News For HRTX;PCRX From the Last 2 Days
There are no results for your query HRTX;PCRX
